A Phase 1b to Assess the Safety and Tolerability of Carboplatin-cyclophosphamide Combined With Atezolizumab, an Antibody That Targets Programmed Death Ligand 1 (PD-L1), in Patients With Advanced Breast Cancer and Gynaecologic Cancer
Latest Information Update: 20 Oct 2021
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cyclophosphamide
- Indications Advanced breast cancer; Cervical cancer; Endometrial cancer; Gynaecological cancer; Ovarian cancer
- Focus Adverse reactions
- Acronyms PROLOG
- 20 Jan 2021 Status changed from active, no longer recruiting to completed.
- 23 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Oct 2020.
- 12 Mar 2019 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.